{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:29:42Z","timestamp":1773815382607,"version":"3.50.1"},"reference-count":82,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA235622"],"award-info":[{"award-number":["R01CA235622"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.clml.2022.04.001","type":"journal-article","created":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T12:16:48Z","timestamp":1649247408000},"page":"652-658","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["SOHO State of the Art Updates and Next Questions | Beyond BCL-2 Inhibition in Acute Myeloid Leukemia: Other Approaches to Leverage the Apoptotic Pathway"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9043-538X","authenticated-orcid":false,"given":"Abhishek","family":"Maiti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing Z.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Andreeff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina Y.","family":"Konopleva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.04.001_bib0001","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.clml.2022.04.001_bib0002","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.04.001_bib0003","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.001_bib0004","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","article-title":"10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial","volume":"7","author":"DiNardo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"30","key":"10.1016\/j.clml.2022.04.001_bib0005","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.20.00572","article-title":"Chemotherapy and venetoclax in elderly acute myeloid leukemia trial (CAVEAT): a phase Ib dose-escalation study of venetoclax combined with modified intensive chemotherapy","volume":"38","author":"Chua","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2022.04.001_bib0006","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1182\/blood-2020-134300","article-title":"Interim analysis of the phase 1b\/2 study of the BCL-2 inhibitor venetoclax in combination with standard intensive AML induction\/consolidation therapy with FLAG-IDA in patients with newly diagnosed or relapsed\/refractory AML","volume":"136","author":"Lachowiez","year":"2020","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.clml.2022.04.001_bib0007","article-title":"Venetoclax (Ven) added to intensive chemo with cladribine, idarubicin, and AraC (CLIA) achieves high rates of durable complete remission with low rates of measurable residual disease (MRD) in pts with newly diagnosed acute myeloid leukemia (AML)","volume":"38","author":"Kadia","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.04.001_bib0008","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3324\/haematol.2020.252569","article-title":"Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens","volume":"106","author":"Maiti","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.04.001_bib0009","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1182\/bloodadvances.2020003934","article-title":"Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs","volume":"5","author":"Masarova","year":"2021","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.clml.2022.04.001_bib0010","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","article-title":"The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discov"},{"issue":"20","key":"10.1016\/j.clml.2022.04.001_sbref0011","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1002\/cncr.33689","article-title":"Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax","volume":"127","author":"Kim","year":"2021","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.clml.2022.04.001_bib0012","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2020-136872","article-title":"Acquired mutations in BAX confer resistance to BH3 mimetics in acute myeloid leukemia","volume":"136","author":"Moujalled","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.001_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2020.07.021","article-title":"Nicotinamide metabolism mediates resistance to venetoclax in relapsed acute myeloid leukemia stem cells","author":"Jones","year":"2020","journal-title":"Cell Stem Cell [Internet]"},{"key":"10.1016\/j.clml.2022.04.001_bib0014","first-page":"1","article-title":"Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells","author":"Stevens","year":"2020","journal-title":"Nat Cancer"},{"issue":"4","key":"10.1016\/j.clml.2022.04.001_bib0015","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic subclones confer resistance to venetoclax-based therapy in acute myeloid leukemia patients","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2022.04.001_bib0016","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1182\/blood-2021-151756","article-title":"Evolution of genomic landscape in acute myeloid leukemia after decitabine and venetoclax","volume":"138","author":"Maiti","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2022.04.001_bib0017","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5306\/wjco.v11.i8.528","article-title":"B-cell lymphoma-2 inhibition and resistance in acute myeloid leukemia","volume":"11","author":"Wilde","year":"2020","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.clml.2022.04.001_bib0018","doi-asserted-by":"crossref","DOI":"10.20517\/cdr.2020.95","article-title":"Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia","author":"Saliba","year":"2020","journal-title":"Cancer Drug Resist [Internet]"},{"key":"10.1016\/j.clml.2022.04.001_bib0019","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/S2152-2650(20)30464-X","article-title":"Harnessing apoptosis in AML","volume":"20","author":"Saxena","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.04.001_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100672","article-title":"Targeting MCL-1 in hematologic malignancies: rationale and progress","volume":"44","author":"Wei","year":"2020","journal-title":"Blood Rev"},{"key":"10.1016\/j.clml.2022.04.001_bib0021","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11523-020-00711-3","article-title":"Targeting apoptosis in acute myeloid leukemia: current status and future directions of BCL-2 inhibition with venetoclax and beyond","volume":"15","author":"Choi","year":"2020","journal-title":"Target Oncol"},{"key":"10.1016\/j.clml.2022.04.001_bib0022","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1182\/blood.2020006785","article-title":"BCL2 and MCL1 inhibitors for hematologic malignancies","volume":"138","author":"Roberts","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.001_bib0023","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1101\/gad.215871.113","article-title":"Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure","volume":"27","author":"Thomas","year":"2013","journal-title":"Genes Dev"},{"key":"10.1016\/j.clml.2022.04.001_bib0024","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1242\/dev.090910","article-title":"Mcl1 regulates the terminal mitosis of neural precursor cells in the mammalian brain through p27Kip1","volume":"140","author":"Hasan","year":"2013","journal-title":"Development"},{"key":"10.1016\/j.clml.2022.04.001_bib0025","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/hep.23126","article-title":"Mcl-1 and Bcl-xL cooperatively maintain integrity of hepatocytes in developing and adult murine liver","volume":"50","author":"Hikita","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.clml.2022.04.001_bib0026","doi-asserted-by":"crossref","first-page":"17012","DOI":"10.1038\/sigtrans.2017.12","article-title":"Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells","volume":"2","author":"Luedtke","year":"2017","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.clml.2022.04.001_bib0027","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/2159-8290.CD-18-0387","article-title":"AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies","volume":"8","author":"Caenepeel","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2022.04.001_bib0028","article-title":"Maximal activation of apoptosis signaling by co-targeting anti-apoptotic proteins in BH3 mimetic-resistant AML and AML stem cells","author":"Carter","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clml.2022.04.001_bib0029","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3324\/haematol.2020.260331","article-title":"Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and re-sensitizes acute myeloid leukemia to BCL-2 inhibition","volume":"107","author":"Carter","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.04.001_bib0030","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2020-141417","article-title":"Co-targeting MCL-1 and BCL-2 is highly synergistic in BH3 Mimetic- and Venetoclax\/hypomethylating agent-resistant and TP53 mutated AML","volume":"136","author":"Carter","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.001_bib0031","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1182\/blood-2021-148014","article-title":"Combined inhibition of Bcl-2 and Mcl-1 circumvents resistance of TP53 deficient\/mutant AML to BH3 mimetics","volume":"138","author":"Carter","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.001_bib0032","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.3324\/haematol.2015.125849","article-title":"Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine\/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia","volume":"100","author":"Zeidner","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.04.001_bib0033","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/cdd.2015.74","article-title":"MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors","volume":"22","author":"Knorr","year":"2015","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.clml.2022.04.001_bib0034","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/s41388-020-01586-4","article-title":"TAS4464, a NEDD8-activating enzyme inhibitor, activates both intrinsic and extrinsic apoptotic pathways via c-Myc-mediated regulation in acute myeloid leukemia","volume":"40","author":"Ochiiwa","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2022.04.001_bib0035","unstructured":"Takeda provides update on phase 3 PANTHER (Pevonedistat-3001) trial [Internet]. Accessed Jan 10, 2022. Available at: https:\/\/www.takeda.com\/newsroom\/newsreleases\/2021\/takeda-provides-update-on-phase-3-panther-pevonedistat-3001-trial\/"},{"key":"10.1016\/j.clml.2022.04.001_bib0036","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.ccell.2017.11.003","article-title":"Synthetic lethality of combined Bcl-2 inhibition and p53 activation in AML: mechanisms and superior antileukemic efficacy","volume":"32","author":"Pan","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2022.04.001_bib0037","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1158\/0008-5472.CAN-12-1365","article-title":"Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism","volume":"73","author":"Rahmani","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2022.04.001_bib0038","doi-asserted-by":"crossref","first-page":"21557","DOI":"10.18632\/oncotarget.4306","article-title":"Inhibition of Bcl-xL overcomes polyploidy resistance and leads to apoptotic cell death in acute myeloid leukemia cells","volume":"6","author":"Zhou","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2022.04.001_bib0039","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/nchembio.1246","article-title":"Structure-guided design of a selective BCL-X L inhibitor","volume":"9","author":"Lessene","year":"2013","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.clml.2022.04.001_bib0040","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","article-title":"Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"11","author":"Pullarkat","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2022.04.001_bib0041","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ccr.2006.10.006","article-title":"Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia","volume":"10","author":"Konopleva","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2022.04.001_bib0042","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s42003-020-01631-8","article-title":"Design and optimisation of dendrimer-conjugated Bcl-2\/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy","volume":"4","author":"Patterson","year":"2021","journal-title":"Commun Biol"},{"key":"10.1016\/j.clml.2022.04.001_bib0043","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1182\/blood-2021-147482","article-title":"NIMBLE: a phase I\/II study of AZD0466 monotherapy or in combination in patients with advanced hematological malignancies","volume":"138","author":"Konopleva","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2022.04.001_bib0044","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1182\/blood-2021-147535","article-title":"Targeting BCL-XL and BCL-2 by protac 753B effectively eliminates AML cells and enhances efficacy of chemotherapy by targeting senescent cells","volume":"138","author":"Jia","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.001_bib0045","doi-asserted-by":"crossref","first-page":"6896","DOI":"10.1038\/s41467-021-27210-x","article-title":"Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity","volume":"12","author":"Lv","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.clml.2022.04.001_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113539","article-title":"Inhibitors of BCL2A1\/Bfl-1 protein: potential stock in cancer therapy","volume":"220","author":"Li","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.clml.2022.04.001_bib0047","doi-asserted-by":"crossref","first-page":"S286","DOI":"10.1016\/S2152-2650(21)01687-6","article-title":"AML-173: BCL2A1: a novel target in refractory\/relapsed AML with FLT3-ITD\/D835 double mutations","volume":"21","author":"Yamatani","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.04.001_bib0048","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/cbic.202000473","article-title":"Selective covalent targeting of anti-apoptotic BFL-1 by a sulfonium-tethered peptide","volume":"22","author":"Liu","year":"2021","journal-title":"ChemBioChem"},{"key":"10.1016\/j.clml.2022.04.001_bib0049","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.chembiol.2020.04.004","article-title":"Identification of a covalent molecular inhibitor of anti-apoptotic BFL-1 by disulfide tethering","volume":"27","author":"Harvey","year":"2020","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.clml.2022.04.001_bib0050","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1182\/blood.2020008528","article-title":"Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas","volume":"137","author":"Boiko","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.001_bib0051","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13046-018-0704-8","article-title":"CDK9 inhibitors in acute myeloid leukemia","volume":"37","author":"Boffo","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.clml.2022.04.001_bib0052","article-title":"Pharmacological reduction of mitochondrial iron triggers a non-canonical BAX\/BAK dependent cell death","author":"Garciaz","year":"2021","journal-title":"Cancer Discov [Internet]"},{"key":"10.1016\/j.clml.2022.04.001_bib0053","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1182\/blood-2018-99-117403","article-title":"Combined BCL-2 and HDAC targeting has potent and TP53 independent activity in AML","volume":"132","author":"Salmon","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.001_bib0054","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.3324\/haematol.2019.233445","article-title":"The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia","volume":"106","author":"Li","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.clml.2022.04.001_bib0055","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/blood-2021-149488","article-title":"An australasian leukemia lymphoma group (ALLG) phase 2 study to investigate novel triplets to extend remission with venetoclax in elderly (INTERVENE) acute myeloid leukemia","volume":"138","author":"Chua","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.001_bib0056","article-title":"Physiological and pharmacological modulation of BAX","author":"Spitz","year":"2021","journal-title":"Trends Pharmacol Sci [Internet]"},{"key":"10.1016\/j.clml.2022.04.001_bib0057","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.ccell.2017.09.001","article-title":"Direct activation of BAX by BTSA1 overcomes apoptosis resistance in acute myeloid leukemia","volume":"32","author":"Reyna","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2022.04.001_bib0058","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/leu.2014.56","article-title":"Inhibitor of Apoptosis (IAP) proteins in hematological malignancies: molecular mechanisms and therapeutic opportunities","volume":"28","author":"Fulda","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.04.001_bib0059","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.clml.2011.03.033","article-title":"Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II study","volume":"11","author":"Schimmer","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.04.001_bib0060","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/1878-0261.12146","article-title":"X-linked inhibitor of apoptosis inhibition sensitizes acute myeloid leukemia cell response to TRAIL and chemotherapy through potentiated induction of proapoptotic machinery","volume":"12","author":"Zhou","year":"2018","journal-title":"Mol Oncol"},{"key":"10.1016\/j.clml.2022.04.001_bib0061","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s43018-021-00177-w","article-title":"Combined inhibition of XIAP and BCL2 drives maximal therapeutic efficacy in genetically diverse aggressive acute myeloid leukemia","volume":"2","author":"Hashimoto","year":"2021","journal-title":"Nat Cancer"},{"issue":"1","key":"10.1016\/j.clml.2022.04.001_bib0062","article-title":"Abstract A091: Phase 1 study of IAP inhibitor ASTX660 in adults with advanced cancers and lymphomas","volume":"17","author":"Mita","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clml.2022.04.001_bib0063","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1158\/1535-7163.MCT-17-0848","article-title":"ASTX660, a novel non-peptidomimetic antagonist of cIAP1\/2 and XIAP, potently induces TNF\u03b1-dependent apoptosis in cancer cell lines and inhibits tumor growth","volume":"17","author":"Ward","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clml.2022.04.001_bib0064","doi-asserted-by":"crossref","first-page":"S177","DOI":"10.1016\/S2152-2650(20)30708-4","article-title":"AML-058: first-in-human study of a trail receptor agonist fusion protein, eftozanermin alfa, in patients with relapsed\/refractory acute myeloid leukemia and diffuse large B-cell lymphoma","volume":"20","author":"Jongen-Lavrencic","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.04.001_bib0065","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-129783","article-title":"First-in-human study of abbv-621, a TRAIL receptor agonist fusion protein, in patients (Pts) with relapsed\/refractory (RR) acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL)","volume":"134","author":"de Jonge","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2022.04.001_bib0066","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2020-137037","article-title":"A phase 1b, open-label study of eftozanermin alfa in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"136","author":"Richardson","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.001_bib0067","unstructured":"Wang B, Matthew T, Kothambawala T, et\u00a0al. Agonistic death receptor 5 (DR5) IgM antibody IGM-8444 induces tumor cell apoptosis in vitro and in vivo and has a favorable in vitro safety profile. 1."},{"key":"10.1016\/j.clml.2022.04.001_bib0068","article-title":"First-in-human study of a trail receptor agonist fusion protein, eftozanermin alfa, in patients with relapsed\/refractory acute myeloid leukemia and diffuse large b-cell lymphoma [Internet]","author":"Jongen-Lavrencic","year":"2020","journal-title":"EHA Library"},{"key":"10.1016\/j.clml.2022.04.001_bib0069","unstructured":"Pipeline \u2013 ONK Therapeutics [Internet]. Accessed May 15, 2021; Available at: https:\/\/www.onktherapeutics.com\/pipeline\/"},{"key":"10.1016\/j.clml.2022.04.001_bib0070","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/bjh.12108","article-title":"Prognostic and therapeutic relevance of c-FLIP in acute myeloid leukaemia","volume":"160","author":"McLornan","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.04.001_bib0071","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1038\/s41467-021-22750-8","article-title":"Cut-like homeobox 1 (CUX1) tumor suppressor gene haploinsufficiency induces apoptosis evasion to sustain myeloid leukemia","volume":"12","author":"Supper","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.clml.2022.04.001_bib0072","article-title":"Development and preclinical evaluation of unique first-in-class small molecule inhibitors of the anti-apoptotic protein FLIP","volume":"1","author":"Higgins","year":"2020","journal-title":"AACR"},{"key":"10.1016\/j.clml.2022.04.001_bib0073","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.celrep.2019.07.001","article-title":"Integrated analysis of TP53 gene and pathway alterations in the cancer genome atlas","volume":"28","author":"Donehower","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.clml.2022.04.001_bib0074","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/gcc.22796","article-title":"The role of TP53 in acute myeloid leukemia: challenges and opportunities","volume":"58","author":"Barbosa","year":"2019","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.clml.2022.04.001_bib0075","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1038\/s41375-020-0949-z","article-title":"MDM2 inhibition: an important step forward in cancer therapy","volume":"34","author":"Konopleva","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.04.001_bib0076","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1182\/blood-2005-12-5148","article-title":"Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia","volume":"108","author":"Kojima","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.001_bib0077","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/1078-0432.CCR-15-0481","article-title":"Results of the phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia","volume":"22","author":"Andreeff","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2022.04.001_bib0078","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2217\/fon-2020-0044","article-title":"MIRROS: a randomized, placebo-controlled, phase III trial of cytarabine \u00b1 idasanutlin in relapsed or refractory acute myeloid leukemia","volume":"16","author":"Montesinos","year":"2020","journal-title":"Future Oncol Lond Engl"},{"issue":"suppl 1","key":"10.1016\/j.clml.2022.04.001_bib0079","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1182\/blood-2019-123711","article-title":"Updated results from the Venetoclax (Ven) in combination with idasanutlin (Idasa) arm of a phase 1b trial in elderly patients (Pts) with relapsed or refractory (R\/R) AML ineligible for cytotoxic chemotherapy","volume":"134","author":"Daver","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.001_bib0080","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrclinonc.2017.151","article-title":"Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others","volume":"15","author":"Sabapathy","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clml.2022.04.001_bib0081","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/S2152-2650(20)30465-1","article-title":"The problem of TP53-mutant MDS\/AML","volume":"20","author":"Sallman","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.04.001_bib0082","article-title":"Aprea therapeutics announces results of primary endpoint from phase 3 trial of eprenetapopt in TP53 mutant myelodysplastic syndromes (MDS)","year":"2021","journal-title":"Aprea Therapeutics [Internet]"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022001136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022001136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:40:15Z","timestamp":1761871215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022001136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":82,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S2152265022001136"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.04.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Beyond BCL-2 Inhibition in Acute Myeloid Leukemia: Other Approaches to Leverage the Apoptotic Pathway","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}